Posts
Hyperphosphatemia is a condition caused by high
levels of phosphorous or phosphate in the blood. This condition may be due to
decreased emission of phosphate, excessive intake of phosphate, and the shift
of phosphate from intracellular to extracellular. High phosphate levels in the
blood can be avoided with the use of phosphate binders or by dietary
restrictions. Phosphate is a chemical found in the human body and contains a mineral
called phosphorous. It is important for the development of bones and teeth and
also converts food into energy for the body. Some other possible causes of
hyperphosphatemia include low levels of parathyroid hormone, high levels of
vitamin D, uncontrolled diabetes, and diabetic ketoacidosis.
The factors such as the growing geriatric population and
increasing prevalence of chronic diseases worldwide are expected to drive the hyperphosphatemia
drugs market in the coming future. Hyperphosphatemia is a primary cause of
mortality and morbidity in people with chronic kidney disease. According to the
Centers for Disease Control and Prevention (CDC), around 37 million adults in
the United States are likely to have chronic kidney disease and most are
undiagnosed. It is rare in the general
population, but in people with chronic kidney disease, the rate
of hyperphosphatemia is at least 70%. Since the increased risk of
death from heart disease and hyperphosphatemia are associated with each other. This,
in turn, increases the risk of heart disease in people suffering from
hyperphosphatemia.
Moreover, high growth potential in untapped
economies such as Brazil, South Africa, China, and India is expected to create robust
growth opportunities for key players involved in the market. However, side
effects associated with hyperphosphatemia drugs, non-adherence to treatment
regimens, and stringent rules/regulations by regulatory bodies are expected to
impede the market growth. For instance, in the human body, the use of
hyperphosphatemia drugs for the treatment of low or high levels of phosphorus
is neither safe nor effective, according to the Food and Drug Administration
(FDA).
In terms of geography, the hyperphosphatemia
drugs market is divided into six regions, such as North America, South America,
Asia Pacific, Europe, the Middle East, and Africa. Increasing launches and
approval of novel drugs are expected to propel the growth of the
hyperphosphatemia drugs market. For instance, in September 2020, Ardelyx
announced that FDA has
accepted its new drug application of tenapanor
for the control of serum phosphorus in adults with chronic kidney disease on
dialysis. Moreover, key players in the market are investing in research and
development activities for the development of novel drugs to treat
hyperphosphatemia. For instance, in September 2019, Ardelyx reported positive
results from the Phase III AMPLIFY study evaluating Tenapanor in Dialysis
Patients.
No comments:
Post a Comment